Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1464327
This article is part of the Research Topic Prognostic Factors for Immunotherapy and Novel Treatments in Genito-Urinary Tumors View all 3 articles

The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets

Provisionally accepted
Xin Li Xin Li 1*Biao Qian Biao Qian 2*Xu Chen Xu Chen 1Maolei Shen Maolei Shen 1*Shankun Zhao Shankun Zhao 3*Xinsheng Zhang Xinsheng Zhang 1*Jian He Jian He 1*
  • 1 Taizhou Central Hospital, Taizhou, China
  • 2 First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province, China
  • 3 Taizhou City Hospital, Taizhou, Jiangsu, China

The final, formatted version of the article will be published soon.

    Urological malignant tumors pose a significant threat to human health, with a high incidence rate each year. Prostate cancer, bladder cancer, and renal cell carcinoma are among the most prevalent and extensively researched urological malignancies. Despite advancements in research, the prognosis for these tumors remains unfavorable due to late detection, postoperative recurrence, and treatment resistance. A thorough investigation into their pathogenesis is crucial for early diagnosis and treatment. Recent studies have highlighted the close association between microRNAs (miRNAs) and cancer progression. miRNAs are small non-coding RNAs composed of 19-23 nucleotides that regulate gene expression by binding to the 3' untranslated region (3'UTR) of target mRNAs, impacting key cellular processes such as proliferation, differentiation, apoptosis, and migration. Dysregulation of miRNAs can disrupt the expression of oncogenes and tumor suppressor genes, contributing to cancer development. Among the various miRNAs studied, miR-152 has garnered attention for its role in urological malignancies. Several studies have indicated that dysregulation of miR-152 expression is significant in these cancers, warranting a comprehensive review of the evidence. This review focuses on the expression and function of miR-152 in prostate cancer, bladder cancer, and renal cell carcinoma, elucidating its mechanisms in cancer progression and exploring its potential as a therapeutic target and biomarker in urological malignancies.

    Keywords: MiR-152, Urological malignancy, Therapeutic target, biomarker, microRNA

    Received: 13 Jul 2024; Accepted: 28 Oct 2024.

    Copyright: © 2024 Li, Qian, Chen, Shen, Zhao, Zhang and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xin Li, Taizhou Central Hospital, Taizhou, China
    Biao Qian, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province, China
    Maolei Shen, Taizhou Central Hospital, Taizhou, China
    Shankun Zhao, Taizhou City Hospital, Taizhou, Jiangsu, China
    Xinsheng Zhang, Taizhou Central Hospital, Taizhou, China
    Jian He, Taizhou Central Hospital, Taizhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.